Vernalis plc enters into drug discovery collaboration with Genentech

4 January 2012

LSE: VER

Vernalis plc (LSE: VER) announced today that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG: OTCQX: RHHBY) utilising Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target.

The financial terms of this collaboration were not disclosed.

Ian Garland, CEO of Vernalis, commented: “We are delighted that Genentech has selected Vernalis to work with it on this target.  Their selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations.  We look forward to building a close working relationship with Genentech and ultimately a successful collaboration.”

James Sabry, Vice President of Genentech Partnering, said “Genentech constantly seeks collaborations like this one to develop therapies that offer the potential of advancing the standard of care and making a meaningful difference in the lives of patients. We are very pleased to enter into this agreement with Vernalis.”

-- ends --

Enquiries:

Vernalis Contacts

Ian Garland, Chief Executive Officer

+44 (0) 118 989 9360

David Mackney, Chief Financial Officer

 

Brunswick Group

 

Jon Coles

+44 (0) 20 7404 5959

Kristin Shine

 

Taylor Rafferty

 

Rob Newman

+44 (0) 20 7614 2900

Faisal Kanth

 

Notes to Editors

About Genentech
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes.  Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations.  Our technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis and Servier.

 


Product

Indication

Pre-Clinical

Phase I

Phase II

Phase III

Marketed

Marketing Rights

PRIORITY PROGRAMMES

CNS Programmes

Frovatriptan

Acute Migraine

 

 

 

 

X

Menarini & Endo Pharma

V158866

Pain

 

X

 

 

 

Worldwide

V81444

Parkinson’s Disease

 

X

 

 

 

Worldwide

 

Oncology Programmes

AUY922

Cancer

 

 

X

 

 

Novartis

CHR2797

Cancer

 

 

X

 

 

Chroma Therapeutics

HSP990

Cancer

 

X

 

 

 

Novartis

V158411

Cancer

X

 

 

 

 

Worldwide

 

Other Therapeutic Areas

V85546

Inflammatory Disease

 

X

 

 

 

Worldwide

LEGACY PROGRAMMES

RPL554

Asthma/ Allergic Rhinitis

 

 

X

 

 

Verona Pharma

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch